Quantcast

Latest Biologic Stories

2014-06-27 12:26:19

DALLAS, June 27, 2014 /PRNewswire/ -- According to the new market research report, "Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018" published by MarketsandMarkets, The global Human Insulin Market crossed $23 Billion in 2013 and is poised to grow at a high double-digit CAGR from...

2014-06-26 23:07:13

Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, was recently invited by the FDA Office of Compliance and Biologics Quality to speak at its Manufacturing Technology Seminar Series. The FDA had specifically requested that Catalent present on its ADVASEPT™ technology, for the advanced aseptic filling of injectable drugs, and Zydis®, Catalent’s Fast Dissolve...

2014-06-25 12:30:18

HLI Co-Founder, Robert Hariri Speaks on Medical Innovation at 2014 BIO International Convention in San Diego LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, today called on physicians, the insurance industry and political leaders to support promising new avenues of medical discovery on behalf of patients with...

2014-06-25 08:30:51

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera(®) SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin(®) SC in...

2014-06-25 08:29:57

-- Company's License Covers C-IBS, Type 2 Diabetes and Obesity -- ROCKVILLE, Md., June 25, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that researchers at Cedars-Sinai Medical Center (Cedars-Sinai) found that eradication of breath methane and reduction of intestinal levels of the most common methanogenic...

2014-06-24 23:03:33

Redwood Bioscience and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the results of an in vivo toxicology study, demonstrating that an Antibody Drug Conjugate (ADC) generated using the proprietary SMARTag™ platform has a better toxicity profile than a conventional ADC. Somerset, N.J. (PRWEB) June 24, 2014 Redwood Bioscience and Catalent Pharma...

2014-06-24 16:24:19

President Leigh Pierce to be a Featured Speaker in Multi-Disciplinary Industry Forum SAN DIEGO, June 24, 2014 /PRNewswire/ -- PacificGMP is a lead sponsor of the California Pavilion at BIO International Convention, June 23-26, 2014 in San Diego, California. The biologics contract development and manufacturer will be available for meetings at Booth 3523 in Hall A of the California Pavilion. On Tuesday, June 24(th) at 3 p.m., PacificGMP President and Chief Scientific Officer Leigh Pierce will...

2014-06-23 12:29:24

Coherus Advances Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., June 23, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA). The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate....

2014-06-23 08:27:48

BEIJING, June 23, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that on June 18, 2014, the Ministry of Finance of China and the State Administration of Taxation of China jointly published a notice to reduce and unify the value added tax ("VAT") rate on sales of a wide range of products in China, which will take effect on July 1, 2014. Pursuant to the...

2014-06-19 23:06:03

Senior Executives from Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, are to present at the forthcoming BIO International conference, which takes place from June 23rd to 26th at the San Diego Convention Center, San Diego, CA. Somerset, N.J. (PRWEB) June 19, 2014 Senior Executives from Catalent Pharma Solutions, the leading global provider of advanced delivery technologies...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related